TROPIC: Phase III Registration Study 146 Sites in 26 Countries
{"Image DocumentName": "TROPIC: Phase III Registration Study 146 Sites in 26 Countries", "Image ImageDescription": "TROPIC slide deck. Slide6,10,13. mCRPC patients who progressed during and after treatment with a docetaxel-based regimen. (N=755) Stratification factors. ECOG PS (0, 1 vs. 2) \u2022 Measurable vs. non-measurable disease. cabazitaxel 25 mg/m\u00b2 q 3 wk + prednisone  for 10 cycles. (n=378) mitoxantrone 12 mg/m\u00b2 q 3 wk + prednisone  for 10 cycles. (n=377)  Oral prednisone/prednisolone: 10 mg daily. Primary endpoint: OS. Secondary endpoints: Progression-free survival (PFS), response rate, and safety. Inclusion: Patients with measurable disease must have progressed by RECIST; otherwise must have had new lesions or PSA progression.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}